Press Releases Clinuvel Pharmaceuticals Limited

Equities

Market Closed - Australian S.E. Other stock markets 07:10:06 08/05/2024 BST			5-day change	1st Jan Change
15.47 ^AUD	+0.52%		+2.79%	-3.31%

04-29	Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3%	MT
03-14	Clinuvel Pharmaceuticals Launches Share Buyback Program	MT

Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors	03-28	AQ
Malibu shines a light on CLINUVEL’s pioneering work in photomedicine	03-05	AQ
CLINUVEL Launches CYACÊLLE, Next Generation Solar Care	28/02/23	AQ
Global SCENESSE® demand drives increased CLINUVEL revenues, earnings	23/02/23	AQ
CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals	02/02/23	AQ
CLINUVEL Trial Results Show Drug Reduces DNA Damage	15/01/23	AQ
Clinuvel Pharmaceuticals : Appendix 4C & Activity Report	25/07/22	PU
Clinuvel Pharmaceuticals : Change of Director’s Interest Notice	23/06/22	PU
Clinuvel Pharmaceuticals : Change of Director’s Interest Notice	14/06/22	PU
Clinuvel Pharmaceuticals : H.C. Wainwright Global Investment Conference Presentation	26/05/22	PU
Clinuvel Pharmaceuticals : H.C. Wainwright Global Investment Conference 2022	26/05/22	PU
Clinuvel Pharmaceuticals : Notice of change of interests of initial substantial holder	25/05/22	PU
Clinuvel Pharmaceuticals : Notice of initial substantial holder	20/05/22	PU
CLINUVEL progresses vitiligo treatment program	10/05/22	AQ
Positive final results in stroke	04/05/22	AQ
Letter to shareholders from CLINUVEL’s CEO	29/04/22	AQ
Clinuvel Pharmaceuticals : CEO letter	29/04/22	PU
Clinuvel Pharmaceuticals : Quarterly Activities/Appendix 4C Cash Flow Report	28/04/22	PU
Clinuvel Pharmaceuticals : Appendix 4C & Activity Report	28/04/22	PU
Clinuvel Pharmaceuticals : Notice of ceasing to be a substantial holder	27/04/22	PU

No results for this search